We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: vericiguat
MedXY News
EnglishTag

vericiguat

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Evaluating Vericiguat in Coronary Vasospasm: Insights from the ViVA Randomized Cross-Over Trial
CardiologyvericiguatCoronary Vasospasm

Evaluating Vericiguat in Coronary Vasospasm: Insights from the ViVA Randomized Cross-Over Trial

By MedXY|Sep 8, 2026

This article reviews the ViVA trial assessing vericiguat, an sGC stimulator, in angina patients with coronary vasospasm but no obstructive coronary artery disease. The study found no significant improvement in vasodilator function or angina

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials
Cardiologycardiovascular outcomesheart failure

Vericiguat in Heart Failure with Reduced Ejection Fraction: Evidence from Pooled Analyses of VICTORIA and VICTOR Trials

By MedXY|Oct 10, 2025

Pooled data from VICTORIA and VICTOR trials demonstrate that vericiguat significantly reduces cardiovascular death and heart failure hospitalization in a wide spectrum of patients with heart failure and reduced ejection fraction, including

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial
Cardiologycardiovascular outcomesheart failure

Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction: Insights from the VICTOR Phase 3 Trial

By MedXY|Oct 10, 2025

The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with accept

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial
Cardiologyheart failureHFrEF

Vericiguat in Stable HFrEF Patients: No Improvement in Composite Endpoint but Significant Reduction in Cardiovascular and All-Cause Mortality – Insights from the VICTOR Trial

By MedXY|Oct 8, 2025

The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential fo

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities